期刊文献+

Effect of oridonin-mediated hallmark changes on inflammatory pathways in human pancreatic cancer(BxPC-3) cells 被引量:6

Effect of oridonin-mediated hallmark changes on inflammatory pathways in human pancreatic cancer(BxPC-3) cells
下载PDF
导出
摘要 AIM:To investigate the effect of oridonin on nuclear transcription factors and to study the relationship between biological behavior and inflammatory factors in human pancreatic cancer(BxPC-3)cells.METHODS:BxPC-3 cells were treated with various concentrations of oridonin,and viability curves were generated to test for inhibitory effects of the drug on cells.The expression of cytokines such as interleukin-1β(IL-1β),IL-6,or IL-33 was detected in BxPC-3 cell supernatants using an enzyme-linked immunosorbent assay(ELISA),and the protein expression of nuclear transcription factors including nuclear factorκB,activating protein-1,signal transducer and activator of transcription 3,bone morphogenetic protein 2,trans-forming growth factorβ1 and sma and mad homologues in BxPC-3 cells was detected using Western blot.Carcinoma hallmark-related proteins such as survivin,vascular endothelial growth factor,and matrix metallopeptidase 2 were also detected using immunoblotting,and intra-nuclear IL-33 expression was detected using immunofluorescent staining.RESULTS:Treatment with oridonin reduced the viability of BxPC-3 cells in a dose dependent manner.The cells exhibited reduced growth following treatment with 8μg/mL oridonin(13.05%±3.21%,P<0.01),and the highest inhibitory ratio was 90.64%±0.70%,which was achieved with oridonin at a dose of32μg/mL.The IC50 value of oridonin in BxPC-3 cells was 19.32μg/mL.ELISA analysis revealed that oridonin down-regulated the inflammatory factors IL-1β,IL-6,and IL-33 in a dose-dependent manner.IL-1βexpression was significantly reduced in the 16 and 32μg/mL treatment groups compared to the control group(12.97±0.45 pg/mL,11.17±0.63 pg/mL vs 14.40±0.38pg/mL,P<0.01).Similar trends were observed for IL-6expression,which was significantly reduced in the 16and 32μg/mL treatment groups compared to the control group(4.05±0.14 pg/mL vs 4.45±0.43 pg/mL,P<0.05;3.95±0.13 pg/mL vs 4.45±0.43 pg/mL,P<0.01).IL-33 expression was significantly reduced in the8,16,and 32μg/mL treatment groups compared to the control group(911.05±14.18 pg/mL vs 945.25±12.09 pg/mL,P<0.05;802.70±11.88 pg/mL,768.54±10.98 pg/mL vs 945.25±12.09 pg/mL,P<0.01).Western blot and immunofluorescent staining analyses suggested that oridonin changed the hallmarks and regulated the expression of various nuclear transcription factors.CONCLUSION:The results obtained suggest that oridonin alters the hallmarks of pancreatic cancer cells through the regulation of nuclear transcription factors. AIM: To investigate the effect of oridonin on nuclear transcription factors and to study the relationship between biological behavior and inflammatory factors in human pancreatic cancer (BxPC-3) cells.
出处 《World Journal of Gastroenterology》 SCIE CAS 2014年第40期14895-14903,共9页 世界胃肠病学杂志(英文版)
基金 Supported by The Qianjiang Talent Project of Zhejiang Province,No.2013R10072 the Natural Science Foundation of Zhejiang Province,Nos.LY14H160037 and LY12H16007
关键词 PANCREATIC cancer Hallmarks ORIDONIN INFLAMMATORY Pancreatic cancer Hallmarks Oridonin Inflammatory pathways Nuclear transcription factors
  • 相关文献

参考文献11

  • 1岳静,沈雯,许健,牟一平,张婷,张斌.基于表达谱芯片的冬凌草甲素抑制胰腺癌BxPC-3细胞的机制研究[J].浙江中医药大学学报,2013,37(5):606-612. 被引量:5
  • 2Xiaoli Jin,Yulian Wu.Berbamine Enhances the Antineoplastic Activity of Gemcitabine in Pancreatic Cancer Cells by Activating Transforming Growth Factor‐β/Smad Signaling[J].Anat Rec.2014(5)
  • 3Alessandra Dicitore,Michele Caraglia,Germano Gaudenzi,Gloria Manfredi,Bruno Amato,Daniela Mari,Luca Persani,Claudio Arra,Giovanni Vitale.Type I interferon-mediated pathway interacts with peroxisome proliferator activated receptor-γ (PPAR-γ): At the cross-road of pancreatic cancer cell proliferation[J].BBA - Reviews on Cancer.2014(1)
  • 4Su‐Feng Chen,Shin Nieh,Shu‐Wen Jao,Min‐Zu Wu,Chia‐Lin Liu,Yun‐Ching Chang,Yaoh‐Shiang Lin.The paracrine effect of cancer‐associated fibroblast‐induced interleukin‐33 regulates the invasiveness of head and neck squamous cell carcinoma[J].J Pathol.2013(2)
  • 5Annett Schmieder,Gabriele Multhoff,Jürgen Radons.Interleukin-33 acts as a pro-inflammatory cytokine and modulates its receptor gene expression in highly metastatic human pancreatic carcinoma cells[J].Cytokine.2012(2)
  • 6A. Rogers,M.J. Smith,P. Doolan,C. Clarke,M. Clynes,J.F. Murphy,A. McDermott,N. Swan,P. Crotty,P.F. Ridgway,K.C. Conlon.Invasive markers identified by gene expression profiling in pancreatic cancer[J].Pancreatology.2012(2)
  • 7Yeon-Sook Choi,Jeong Ae Park,Jihye Kim,Seung-Sik Rho,Hyojin Park,Young-Myeong Kim,Young-Guen Kwon.Nuclear IL-33 is a transcriptional regulator of NF-κB p65 and induces endothelial cell activation[J].Biochemical and Biophysical Research Communications.2012(2)
  • 8Douglas Hanahan,Robert A. Weinberg.Hallmarks of Cancer: The Next Generation[J]. Cell . 2011 (5)
  • 9Giovanni Vitale,Silvia Zappavigna,Monica Marra,Alessandra Dicitore,Stefania Meschini,Maria Condello,Giuseppe Arancia,Sara Castiglioni,Paola Maroni,Paola Bendinelli,Roberta Piccoletti,Peter M. van Koetsveld,Francesco Cavagnini,Alfredo Budillon,Alberto Abbruzzese,Leo J. Hofland,Michele Caraglia.The PPAR-γ agonist troglitazone antagonizes survival pathways induced by STAT-3 in recombinant interferon-β treated pancreatic cancer cells[J].Biotechnology Advances.2011(1)
  • 10Junchao Guo,J?rg Kleeff,Yupei Zhao,Junsheng Li,Thomas Giese,Irene Esposito,Markus Büchler,Murray Korc,Helmut Friess.Yes-associated protein (YAP65) in relation to Smad7 expression in humanpancreatic ductal adenocarcinoma[J].International Journal of Molecular Medicine.2006(5)

二级参考文献21

  • 1龚新雷,秦叔逵.胰腺癌的药物治疗进展[J].临床肿瘤学杂志,2007,12(1):68-76. 被引量:8
  • 2Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009[J]. CA Cancer J Clin, 2009, 59(4):225-249.
  • 3Loos M, Kleef J, Friess H, et al. Surgical treatment of pancreatic cancer[J]. Ann N Y Acad Sci, 2008, 1138:169- 180.
  • 4Barry S. Taylor, Nikolaus Sehuhz, Haley Hieronymus, et al. Integrative genomic profiling of human prostate cancer[J]. Cancer Cell, 2010, 18(1): 11-22.
  • 5Liu Z, Ouyang L, Peng H, et al. Oridonin: targeting programmed cell death pathways as an anti-tumour agent[J]. Cell Prolif, 2012, 45(6): 499-507.
  • 6Chen SS, Michael A, Butler-Manuel SA. Advances in the treatment of ovarian cancer: a potential role of antiinflammatory phytoehemicals[J].Discov Med, 2012, 13 (68):7-17.
  • 7Li CY, Wang EQ, Cheng Y, et al. Oridonin: An active diterpenoid targeting cell cycle arrest, apoptotic and autophagic pathways for cancer therapeutics Int J Biochem Cell Biol, 2011, 43(5): 701-704.
  • 8Manuel Hida/go,M.D.Panereatie Cancer[J].The New England Journal of Medicine, 2010,362:1605-1617.
  • 9Charles G. Mullighan, Salil Goorha, Ina Radtke. Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia[J]. Nature, 2007, 446(12): 758- 764.
  • 10Li JD, Feng QC, Li GS. Differential gene expression profiling of oesophageal squamous cell carcinoma by DNA microarray and bioinformatics analysis[J].The Journal of International Medical Research, 2010, 38: 1904-1912.

共引文献55

同被引文献35

引证文献6

二级引证文献19

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部